William Blair Weighs in on Pyxis Oncology FY2027 Earnings

Pyxis Oncology, Inc. (NASDAQ:PYXS) – Investment analysts at William Blair issued their FY2027 earnings per share estimates for Pyxis Oncology in a research report issued to clients and investors on Tuesday, March 18th. William Blair analyst A. Hsieh forecasts that the company will post earnings per share of ($1.27) for the year. William Blair has a “Market Perform” rating on the stock. The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.04) per share.

Several other equities analysts have also recently issued reports on PYXS. Royal Bank of Canada restated an “outperform” rating and issued a $8.00 price target on shares of Pyxis Oncology in a research report on Wednesday. HC Wainwright reissued a “buy” rating and set a $5.00 price target on shares of Pyxis Oncology in a research note on Wednesday. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.20.

Pyxis Oncology Stock Up 4.7 %

Shares of PYXS stock opened at $1.12 on Thursday. The stock has a market capitalization of $66.60 million, a PE ratio of -1.09 and a beta of 1.11. Pyxis Oncology has a 52-week low of $0.99 and a 52-week high of $6.18. The stock’s 50-day moving average price is $1.33 and its 200 day moving average price is $2.38.

Pyxis Oncology (NASDAQ:PYXS) last posted its quarterly earnings results on Tuesday, March 18th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.01.

Institutional Trading of Pyxis Oncology

A number of institutional investors have recently added to or reduced their stakes in PYXS. ProShare Advisors LLC purchased a new stake in Pyxis Oncology during the 4th quarter worth $26,000. Caption Management LLC purchased a new position in Pyxis Oncology in the 4th quarter valued at about $35,000. Ameriprise Financial Inc. purchased a new position in Pyxis Oncology in the 4th quarter valued at about $35,000. Commonwealth Equity Services LLC boosted its position in Pyxis Oncology by 61.5% in the 4th quarter. Commonwealth Equity Services LLC now owns 26,250 shares of the company’s stock valued at $41,000 after buying an additional 10,000 shares during the last quarter. Finally, Graham Capital Management L.P. purchased a new position in Pyxis Oncology in the 4th quarter valued at about $47,000. 39.09% of the stock is owned by hedge funds and other institutional investors.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.